Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastasesReportar como inadecuado




Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

International Journal of Colorectal Disease

, Volume 25, Issue 10, pp 1243–1249

First Online: 24 June 2010Accepted: 10 June 2010

Abstract

PurposeAdjuvant systemic 5-fluorouracil 5-FU-based chemotherapy improves survival after resection of synchronous colorectal liver metastases CLMs, but not metachronous. We retrospectively examined if adjuvant chemotherapy with new regimen containing oxaliplatin or irinotecan improved survivals after resection of metachronous CLMs.

MethodsBetween 2000 and 2007, 52 patients having undertaken resection of metachronous CLMs with curative intent were identified from Taipei Veterans General Hospital hospitalization registry. One patient with perioperative mortality and another being lost to follow-up within 3 months after metastasectomy were excluded. Thirty-one patients experienced six to 12 cycles of FOLFOX or FOLFIRI chemotherapy while 19 patients with 5-FU-leucovorin LV-based chemotherapy following CLM resection. The primary end point was disease-free survival DFS and secondary end point, overall survival OS.

ResultsBy the univariate analysis, median DFS was 34.3 months in the FOLFOX-FOLFIRI group vs 14.2 months in the 5-FU-LV group P = 0.022. The median OS and 5-year survival rates were longer than 57.7 months not reached, with median follow-up of 35.5 months and 54.0%, respectively, in the FOLFOX-FOLFIRI group compared to 49 months and 34.6% in the 5-FU-LV group P = 0.027. FOLFOX-FOLFIRI chemotherapy was shown by multivariate analyses to be an independent factor predicting a better DFS hazard ratio HR = 0.37; 95% CI: 0.15–0.94; P = 0.036 and a better OS HR = 0.27; 95% CI: 0.083–0.86, P = 0.026 than 5-FU-LV-based.

ConclusionsAdjuvant FOLFOX-FOLFIRI chemotherapy following resection of metachronous CLMs is demonstrated to have better DFS and OS than 5-FU-LV chemotherapy.

KeywordsAdjuvant chemotherapy Colorectal liver metastasis Irinotecan Metachronous Oxaliplatin Jin-Hwang Liu, Yao-Yu Hsieh, and Wei-Shone Chen contributed equally to this work

Download fulltext PDF



Autor: Jin-Hwang Liu - Yao-Yu Hsieh - Wei-Shone Chen - Yen-Ning Hsu - Gar-Yang Chau - Hao-Wei Teng - Kuang-Liang King - Tzu-Chen 

Fuente: https://link.springer.com/article/10.1007/s00384-010-0996-4







Documentos relacionados